CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-05 | BASTA JAMES EVP, General Counsel | Sale | −10,397 | $9.21 | $96K | 101,528 |
| 2026-01-05 | Cohen Fred E Director | Purchase | +150,000 | $9.35 | $1.4M | 207,453 |
| 2026-01-05 | Lebwohl David EVP, Chief Medical Officer | Sale | −11,903 | $9.21 | $110K | 121,249 |
| 2026-01-05 | Clark Eliana EVP, Chief Technical Officer | Sale | −9,515 | $9.21 | $88K | 87,118 |
| 2026-01-05 | Dulac Edward J III EVP, Chief Financial Officer | Sale | −6,379 | $9.21 | $59K | 99,683 |
| 2026-01-05 | Dube Michael P VP, Chief Accounting Officer | Sale | −2,989 | $9.21 | $28K | 52,277 |
| 2025-12-12 | LEONARD JOHN M President and CEO | Option exercise 10b5-1 | +8,557 | $6.83 | $58K | 1,047,485 |
| 2025-12-12 | LEONARD JOHN M President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,557 | 0 | ||
| 2025-12-11 | LEONARD JOHN M President and CEO | Option exercise 10b5-1 | +49,959 | $6.83 | $341K | 1,127,074 |
| 2025-12-11 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −49,959 | $9.49 | $474K | 1,077,115 |
| 2025-12-11 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −32,832 | $9.47 | $311K | 1,044,283 |
| 2025-12-11 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −5,355 | $9.59 | $51K | 1,038,928 |
| 2025-12-11 | LEONARD JOHN M President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −49,959 | 8,557 | ||
| 2025-10-01 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | −31 | $17.38 | $539 | 105,184 |
| 2025-10-01 | Dube Michael P VP, Chief Accounting Officer | Sale | −1,871 | $17.38 | $33K | 55,266 |
| 2025-08-20 | CHASE WILLIAM J Director | Purchase | +100,000 | $10.03 | $1.0M | 134,693 |
| 2025-07-23 | Dulac Edward J III EVP, Chief Financial Officer | Sale | −7,462 | $14.02 | $105K | 106,062 |
| 2025-07-02 | Dube Michael P VP, Chief Accounting Officer | Sale | −2,503 | $9.95 | $25K | 57,137 |
| 2025-07-01 | Clark Eliana EVP, Chief Technical Officer | Sale | −1,022 | $9.82 | $10K | 95,369 |
| 2025-07-01 | GOODMAN JESSE Director | Sale 10b5-1 | −1,547 | $9.23 | $14K | 24,359 |
Page 3 of 40 · 783 trades